clenbuterol has been researched along with Necrosis in 4 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have investigated the dose- and time-dependency of myocyte apoptosis and necrosis induced by the beta2-adrenergic receptor agonist, clenbuterol, with the aim of determining whether myocyte apoptosis and necrosis are two separate processes or a continuum of events." | 3.73 | Dose-dependent apoptotic and necrotic myocyte death induced by the beta2-adrenergic receptor agonist, clenbuterol. ( Burniston, JG; Chester, N; Clark, WA; Goldspink, DF; Tan, LB, 2005) |
| "Myocyte-specific necrosis in the heart and soleus muscle of adult male Wistar rats was investigated in response to a single subcutaneous injection of the anabolic beta(2)-adrenergic receptor agonist clenbuterol." | 3.71 | Myotoxic effects of clenbuterol in the rat heart and soleus muscle. ( Burniston, JG; Clark, WA; Colyer, J; Goldspink, DF; Ng, Y; Tan, LB, 2002) |
| " Hepatotoxic compounds such as CCl4, galactosamine and thioacetamide that cause hepatic necrosis and compounds such as hydrazine and ethionine that cause fatty liver all result in elevated urinary taurine levels in rats." | 3.69 | Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro. ( Timbrell, JA; Waterfield, CJ, 1996) |
| " However, such doses may also induce myocyte death in the heart and skeletal muscles and hence may not be safe doses for humans." | 1.33 | Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles. ( Burniston, JG; Clark, WA; Goldspink, DF; Tan, LB, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burniston, JG | 3 |
| Ng, Y | 1 |
| Clark, WA | 3 |
| Colyer, J | 1 |
| Tan, LB | 3 |
| Goldspink, DF | 3 |
| Chester, N | 1 |
| Timbrell, JA | 1 |
| Waterfield, CJ | 1 |
4 other studies available for clenbuterol and Necrosis
| Article | Year |
|---|---|
Myotoxic effects of clenbuterol in the rat heart and soleus muscle.
Topics: Adrenergic beta-Agonists; Animals; Clenbuterol; Dose-Response Relationship, Drug; Heart; Injections, | 2002 |
Dose-dependent apoptotic and necrotic myocyte death induced by the beta2-adrenergic receptor agonist, clenbuterol.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Caspase 3; Caspases; Cell Count; Clenbuterol; Dose-Res | 2005 |
Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Clenbuterol; Dose-Response Relationship, Drug; Hypertr | 2006 |
Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro.
Topics: Animals; Biomarkers; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Cells, Cultured; Clenbute | 1996 |